Imatinib mesylate (IM), a small molecule tyrosine kinase inhibitor that abrogates KIT and PDGFRA activity, is a highly effective treatment for KIT/PDGFRA -driven metastatic GIST and leads to stable disease in approximately 85% of cases [7, 8]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.